Congenital Heart Disease
Conditions
Keywords
copeptin, pediatric cardiac surgery, heart lung machine
Brief summary
This study evaluates the relevance of Copeptin in children with congenital heart disease undergoing cardiac surgery with the need of cardiopulmonary bypass. Three blood samples are taken of each patient. The first and second sample are collected in the operation room before and after the procedure and the third sample on the first postoperative day at the intensive care unit.
Detailed description
Objective: Vasopressin is a hormone secreted by the posterior pituitary gland. Its main functions are constriction of blood vessels and reabsorption of water and thereby regulating water balance and hemodynamics of the body. Copeptin is a cleavage product in the synthesis of vasopressin and is released in equimolar amounts. Its stability makes it easier to determine the amount of vasopressin. It is known, that the use of a heart-lung machine in cardiac procedures has effects on the water balance of the body and may affect the vasopressin secretion. The aim of this prospective clinical trial is, to figure out if copeptin would be suitable for perioperative risk evaluation in neonates and children with congenital heart disease after surgery with the use of a heart-lung machine. Hypotheses: The primary outcome endpoint of this study is the change in copeptin concentration perioperatively in patients with congenital heart disease, with the use of heart-lung machine. Secondary outcome endpoints are correlations between copeptin concentration and complexity of the procedure (based on the aristotle basic score), clinical status and the perfusion times of the heart-lung machine.
Interventions
None listed
Sponsors
Claudia Herbst
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 6 Years
Healthy volunteers
No
Inclusion criteria
* ≤6 years of age * CHD * need of HLM for surgery * Informed consent of parents * not participating in other studies
Exclusion criteria
* Preoperative ventilatory support * Preoperative circulatory support (ECMO, VAD) * Diabetes insipidus * Preoperative CPR * Preoperative shock * Preoperative sepsis * Preoperative vasopressin application
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Copeptin concentrations | baseline and up to one day | Change of Copeptin concentrations between the baseline and first postoperative measurement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intubation | up to one day | Duration of intubation time |
| Cardiopulmonary bypass | up to one day | Total time of cardiopulmonary bypass and aortic cross clamp time. |
| ICU stay | up to one day | Length of ICU stay |
| Complexity of procedures | up to one day | The surgical complexity of the procedures undergone by the patients will be shown by using a scoring system developed for this purpose named Aristotle Score |
Countries
Austria
Outcome results
None listed